Skip to content
  • Home
  • World News
  • Business
  • Aviation
195 news

195News

All the news that's fit to print

  • Home
  • World News
  • Business
  • Aviation
  • Toggle search form
  • United States and Cuba Resume Law Enforcement Dialogue World News
  • Author Ruben Gonzales Inspires with Broken Walk: Searching for Wisdom World News
  • ACI Jet & CMS Complete Inflight Cabin Management System STC Applicable to Challenger 604, 605, and 650 Aircraft Aviation
  • Massachusetts Opens Probe Targeting Gov. DeSantis Over Sending Migrants To Martha’s Vineyard
    Massachusetts Opens Probe Targeting Gov. DeSantis Over Sending Migrants To Martha’s Vineyard World News
  • How did Germany end its reliance on Russian gas? – BBC News World News
  • War Day 166: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych  & #Feygin
    War Day 166: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • Vintage Luxury Brand Two Authenticators Inc. (2a) Solidifies Management Team to Underpin Exponential Growth Business
  • EEG Analysis Specialist SLOWAVE INC. Collaborates with Ajou University Hospital on Delirium Research World News

Rapid Dose Announces Proposed Equity Private Placement Financing

Posted on January 29, 2024 By NewsEditor

Rapid Dose Therapeutics Corp. (CSE:DOSE)

BURLINGTON, ON, CANADA, January 20, 2024 /EINPresswire.com/ — Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it plans to complete an equity private placement financing (the “Financing”) for up to $7,000,000 of gross proceeds, consisting of up to 41,176,470 units (the “Units”) at a price of $0.17 per Unit. Each Unit will consist of one (1) common share of the Company (a “Common Share”) and one (1) common share purchase warrant of the Company (a “Warrant”). Each Warrant will be exercisable to acquire one (1) Common Share at a price of $0.20 per Common Share for a term of two (2) years from the date of issuance of such Warrant.

The Company has entered into an agreement with Meadowbank Asset Management Inc. (the “Agent”) in respect of the Financing. The Agent shall be paid a cash commission equal to 6% of the aggregate gross proceeds raised pursuant to the Financing from investors introduced to the Company by the Agent. The Company shall also issue such number of non-transferable agent warrants (each, an “Agent Warrant”) as is equal to 6% of the number of Units issued to investors in the Financing that were introduced to the Company by the Agent. Each Agent Warrant will be exercisable to acquire one (1) Common Share at a price of $0.20 per Common Share for a term of two (2) years from the date of issuance of such Agent Warrant. The Agent shall have a one-time right to nominate two (2) independent directors to the Company’s board of directors.

The Company intends to use the proceeds from the Financing for research and development, capital expansion and working capital purposes. The Financing may close in one or more tranches. All securities issued on the Financing will be subject to a four month hold from the applicable date of closing.

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company’s flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. For more information about the Company, visit www.rapid-dose.com.

Contacts:

RDT Investor Contact:

Mark Upsdell, CEO

[email protected]

416-477-1052

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forwardlooking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States. The securities described in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

MARK UPSDELL
Rapid Dose Therapeutics Corp.
+1 416-477-1052
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Instagram
YouTube

You just read:

News Provided By

January 20, 2024, 18:40 GMT


EIN Presswire’s priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content.
As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone’s Internet News Presswire™,
tries to define some of the boundaries that are reasonable in today’s world. Please see our
Editorial Guidelines
for more information.



Article originally published on www.einpresswire.com as Rapid Dose Announces Proposed Equity Private Placement Financing

Business

Post navigation

Previous Post: LTV Day 540 – Two Main Goals of Counter-Offensive Campaign – Latynina.tv – Alexey Arestovych
Next Post: Bulk Petroleum And Chemical Storage Market Size, Share, Revenue, Trends And Drivers For 2024-2033

Related Posts

  • Data Visualization Tools Market Expected to Reach .24 Billion by 2030 Driven by Robust Industry Expansion
    Data Visualization Tools Market Expected to Reach $17.24 Billion by 2030 Driven by Robust Industry Expansion Business
  • LiveInCare USA Analysis Finds Companionship in 25% of Recent Live-In Care Requests Business
  • Combining Style and Sustainability: Studio St. Germain Featured in SketchUp Blog Business
  • Truss Financial Group Introduces Dedicated Spanish-Language Loan Services Business
  • Midtronics Unveils MDX-AI to Improve Battery Diagnostics Business
  • United Water Restoration Group Protects Ormond Beach Homes From Water Damage Business
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« Oct    
last celebrity gossip
Gossip Stone - celebrity life and gossip

Recent Posts

  • Ataxia Market Analysis Report Exploring Demand Patterns and Competitive LandscapeNovember 20, 2026
  • SEOPS Expands Waymaker Rideshare Program with Third Falcon 9 Launch with SpaceXNovember 20, 2026
  • The Assistive Technologies Market for Visually Impaired Expected to Reach $12.71 Billion by 2030November 19, 2026
  • Sabio Group hires Simon Foot to lead Sabio Consulting as AI-first Transformation AcceleratesNovember 19, 2026
  • Atenolol Market Outlook Report Including Segment Analysis and Strategic Industry InsightsNovember 18, 2026
Brand Values Content
VUGA Enterprises - media network PR & Marketing
  • GEO Satellite Market In 2029 Aviation
  • RBMA’s Radiology Patient Action Network Study Shows Nearly Half of Women Not Receiving Recommended Mammograms Business
  • Minja Yan Launches Campaign For Clark County Commission District F World News
  • Fernando Aguirre, Vice Chairman of DHS Ventures, Announced Acquisition of Grupo SILMEX for $750M Gaining Presence in Mexico Business
  • How She Bought a Business for $2,500 and Helps Others Do the Same Business
  • Independent Contract Nurses: Tax Season is Here Business
  • Golovanov #34: Why Divide Ukrainians into Classes? Holovanov, Arestovych. Ukraine War Chronicles. World News
  • U.S. Special Envoy for Yemen Lenderking’s Travel to Saudi Arabia, Oman, and the UAE World News
aerospace company
stem cell clinic in kiev
medical spa in miami
Fashion TV free

Copyright © 2026 195 News. All Rights Reserved by Coolaser

Powered by .